Information Provided By: 
Fly News Breaks for March 2, 2018
NVS, CNAT
Mar 2, 2018 | 08:16 EDT
Oppenheimer analyst Jay Olson initiated Conatus (CNAT) with an Outperform rating and $16 price target based on his view that significant value for shareholders, physicians and patients can be unlocked by the company's "unique" approach to liver disease. In a research note to investors, Olson said he sees emricasan as well positioned to potentially demonstrate efficacy in a broad range of liver diseases, including NASH, adding that the program is viewed as "partially de-risked" through its partnership with Novartis (NVS).
News For CNAT;NVS From the Last 2 Days
NVS
Apr 23, 2024 | 13:58 EDT
NVS
Apr 23, 2024 | 06:36 EDT
